These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 7480380)
61. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. Hori H; Yoshimura R; Katsuki A; Sugita AI; Atake K; Nakamura J J Psychiatr Res; 2013 Dec; 47(12):1843-8. PubMed ID: 24054464 [TBL] [Abstract][Full Text] [Related]
62. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. Lee BJ; Lee JG; Kim YH J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979 [TBL] [Abstract][Full Text] [Related]
63. Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population. Martin IC Acta Psychiatr Scand; 1975 Feb; 51(2):110-8. PubMed ID: 235189 [TBL] [Abstract][Full Text] [Related]
64. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. Wittorf A; Sickinger S; Wiedemann G; Klingberg S Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323 [TBL] [Abstract][Full Text] [Related]
65. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670 [TBL] [Abstract][Full Text] [Related]
66. Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study. Kagerer S; Winter C; Möller HJ; Soyka M Neuropsychobiology; 2003; 47(4):212-8. PubMed ID: 12824745 [TBL] [Abstract][Full Text] [Related]
67. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Davidson M; Galderisi S; Weiser M; Werbeloff N; Fleischhacker WW; Keefe RS; Boter H; Keet IP; Prelipceanu D; Rybakowski JK; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Kahn RS Am J Psychiatry; 2009 Jun; 166(6):675-82. PubMed ID: 19369319 [TBL] [Abstract][Full Text] [Related]
68. Tardive dyskinesia and steady-state serum levels of thiothixene. Yesavage JA; Tanke ED; Sheikh JI Arch Gen Psychiatry; 1987 Oct; 44(10):913-5. PubMed ID: 2889439 [TBL] [Abstract][Full Text] [Related]
69. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Perkins DO; Johnson JL; Hamer RM; Zipursky RB; Keefe RS; Centorrhino F; Green AI; Glick IB; Kahn RS; Sharma T; Tohen M; McEvoy JP; Weiden PJ; Lieberman JA; Schizophr Res; 2006 Mar; 83(1):53-63. PubMed ID: 16529910 [TBL] [Abstract][Full Text] [Related]
70. Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative. Marder SR; Fenton W; Youens K Am J Psychiatry; 2004 Jan; 161(1):25. PubMed ID: 14702244 [No Abstract] [Full Text] [Related]
71. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I; J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069 [TBL] [Abstract][Full Text] [Related]
72. Neuropsychological impairments in patients with schizophrenia: stability and prediction of outcome. Gråwe RW; Levander S Acta Psychiatr Scand Suppl; 2001; (408):60-4. PubMed ID: 11730074 [TBL] [Abstract][Full Text] [Related]
73. [Comparative study of thiothixene and trifluoperazine in schizophrencs in the acute phase]. Hillel JM; Albert JM; Tetreault L Encephale; 1970; 59(2):162-79. PubMed ID: 5458711 [No Abstract] [Full Text] [Related]
74. A randomised controlled trial of prophylactic neuroleptic treatment. Crow TJ; MacMillan JF; Johnson AL; Johnstone EC Br J Psychiatry; 1986 Feb; 148():120-7. PubMed ID: 2870753 [TBL] [Abstract][Full Text] [Related]
75. [From neuroleptics to antipsychotics: the cognitive and emotional impact]. Blin O; Fakra E; Tardieu S; Micallef J Encephale; 2002; 28 Spec No 2 Pt 2():S16-8. PubMed ID: 12587350 [No Abstract] [Full Text] [Related]
76. [Tolerance of neuroleptics, deficit syndrome and cognitive functions]. Kahn JP Encephale; 1996 Jun; 22 Spec No 2():49-54. PubMed ID: 8767043 [TBL] [Abstract][Full Text] [Related]
77. Cognitive deficits in adolescents with schizophrenia undergoing antipsychotic treatment. Chabrol H; Peresson G; Bonnet D Am J Psychiatry; 1999 Mar; 156(3):497-8. PubMed ID: 10080578 [No Abstract] [Full Text] [Related]
78. Cognitive deficits as treatment targets in schizophrenia. Gold JM Schizophr Res; 2004 Dec; 72(1):21-8. PubMed ID: 15531404 [TBL] [Abstract][Full Text] [Related]
79. [Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics]. Danilov DS; Tiul'pin IuG Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(2):25-9. PubMed ID: 18379518 [TBL] [Abstract][Full Text] [Related]
80. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Liu SK; Chen WJ; Chang CJ; Lin HN Neuropsychopharmacology; 2000 Mar; 22(3):311-9. PubMed ID: 10693159 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]